Want to see STTK full AI Analyst Report?
Top Page
Shattuck Labs
(NASDAQ:STTK)
Select Model
Select Model
Rating:56Neutral
Price Target:
$6.00
▼(-25.56% Downside)
Action:Reiterated
Date:08/11/26
The score is held back primarily by weak financial performance (minimal revenue scale, ongoing large losses, and sustained cash burn despite a low-leverage balance sheet). Technicals are moderately positive with price above key moving averages and a positive MACD, while valuation remains pressured due to losses and no dividend support. Recent corporate events add some upside from encouraging clinical data and improved funding, tempered by dilution considerations.
Positive Factors
Low Leverage
Minimal debt relative to equity gives Shattuck financial flexibility while it advances its pipeline. The sizable asset base provides a cushion against operating volatility and reduces near-term balance-sheet strain, although continued losses could gradually erode this strength.
Negative Factors
Minimal Revenue and Deep Losses
The very small revenue base and substantial net loss show that Shattuck has not yet established commercial scale or sustainable profitability. Negative gross profit further weakens earnings quality, leaving future value heavily dependent on successful clinical development and eventual product revenue.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Minimal debt relative to equity gives Shattuck financial flexibility while it advances its pipeline. The sizable asset base provides a cushion against operating volatility and reduces near-term balance-sheet strain, although continued losses could gradually erode this strength.
Read all positive factors
Shattuck Labs (STTK) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$586.12M
Dividend YieldN/A
Average Volume (3M)1.47M
Price to Earnings (P/E)―
Beta (1Y)1.90
Revenue Growth-66.63%
EPS Growth57.89%
CountryUS
Employees40
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.51
Shares Outstanding100,363,250
10 Day Avg. Volume1,239,112
30 Day Avg. Volume1,472,773
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)3.08
Price to Sales (P/S)253.99
P/FCF Ratio-6.36
Enterprise Value/Market Cap1.19
Enterprise Value/Revenue695.04
Enterprise Value/Gross Profit-92.56
Enterprise Value/Ebitda-14.18
Forecast
1Y Price Target
$15.40Price Target Upside91.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-0.49
Revenue Forecast (FY)$105.00K
Shattuck Labs Business Overview & Revenue Model
Company Description
Shattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage. Its core mission is to create innovative therapeutics designed to combat both cancer and autoimmune diseases. The company...
Shattuck Labs Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
72
Positive
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.00M | 1.00M | 5.72M | 1.66M | 652.00K | 30.02M |
| Gross Profit | -7.51M | -1.95M | 827.00K | -2.38M | -81.55M | 28.64M |
| EBITDA | -49.00M | -45.12M | -71.58M | -83.26M | -98.87M | -43.59M |
| Net Income | -52.57M | -48.81M | -75.41M | -87.30M | -101.94M | -44.97M |
Balance Sheet | ||||||
| Total Assets | 220.67M | 91.03M | 91.05M | 159.56M | 205.32M | 298.58M |
| Cash, Cash Equivalents and Short-Term Investments | 63.30M | 78.06M | 72.99M | 130.63M | 161.28M | 268.80M |
| Total Debt | 2.67M | 2.42M | 3.41M | 4.20M | 4.90M | 0.00 |
| Total Liabilities | 9.53M | 8.64M | 11.42M | 14.86M | 29.17M | 26.80M |
| Stockholders Equity | 211.14M | 82.39M | 79.63M | 144.71M | 176.16M | 271.79M |
Cash Flow | ||||||
| Free Cash Flow | -41.24M | -39.95M | -60.57M | -81.64M | -106.11M | -65.04M |
| Operating Cash Flow | -41.03M | -39.88M | -60.52M | -81.23M | -94.50M | -57.12M |
| Investing Cash Flow | -144.59M | -7.89M | -8.51M | 110.86M | 49.44M | -10.44M |
| Financing Cash Flow | 198.44M | 44.57M | 787.00K | 48.62M | 171.00K | 1.93M |
Shattuck Labs Technical Analysis
Negative
8.06
Price Trends
6.53
Negative
6.39
Negative
6.00
Negative
Market Momentum
-0.27
Positive
42.42
Neutral
39.75
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For STTK, the sentiment is Negative. The current price of 8.06 is above the 20-day moving average (MA) of 6.00, above the 50-day MA of 6.53, and above the 200-day MA of 6.00, indicating a bearish trend. The MACD of -0.27 indicates Positive momentum. The RSI at 42.42 is Neutral, neither overbought nor oversold. The STOCH value of 39.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for STTK.
Shattuck Labs Risk Analysis
Shattuck Labs disclosed 56 risk factors in its most recent earnings report. Shattuck Labs reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Shattuck Labs Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $586.12M | -10.94 | -43.57% | ― | -66.63% | 57.89% | |
53 Neutral | $460.90M | -5.15 | -23.64% | ― | -76.20% | 52.86% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | $508.29M | -4.73 | -45.11% | ― | ― | -18.84% | |
42 Neutral | $134.94M | -1.12 | -57.92% | ― | -19.07% | 2.07% | |
42 Neutral | $114.12M | -0.08 | 250.02% | ― | ― | -2012.66% | |
41 Neutral | $126.07M | -5.20 | -21.11% | ― | ― | 73.28% |
* Healthcare Sector Average
STTK
Shattuck Labs
5.58
3.73
201.62%
NGNE
Neurogene
26.08
-2.63
-9.16%
NERV
Minerva Neurosciences
2.39
-2.48
-50.92%
AVXL
Anavex Life Sciences
1.36
-7.38
-84.44%
VYGR
Voyager Therapeutics
2.02
-2.53
-55.60%
OVID
Ovid Therapeutics
2.47
0.91
58.33%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.